Hospital Universitario HM Sanchinarro, Medical Physics Department, Madrid, Spain 4 Hospital Universitario HM Puerta del Sur, Medical Physics Department, Madrid, Spain Purpose or Objective: To review stereotactic body radiation therapy (SBRT) safety and local control utility in malignant tumor of the pancreas based in a single center experience since February 2014.
Material and Methods:
A systematic review was done. Thirteen patients were treated with SBRT. Eleven patients had a primary pancreatic tumor and two patients had metastatic affectation of the pancreas. In those patients with primary pancreatic cancer, four patients were treated with a radical intent, five as a part of a neoadjuvant treatment and four patients with a palliative intent. All of the treated tumors had a diameter bigger than 2 cm. At least 2 fiducials were located into the tumor, guided by endoscopic ultrasound. All the treatments included CT or PET-CT for GTV delineation, intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) with intrafraction control of tumor motion with a Novalis Exactrac Adaptive Gating System. 50 Gy in 10 fractions were prescribed in eleven patient, one patient was treated with 35Gy in 5 fractions and one patient was treated with 40Gy in 10 fraction.
Results: Pancreatic SBRT was very well tolerated in our cohort of patients. No grade 3 or higher toxicity was observed. Only 3 patients developed grade 2 epigastric pain and/or grade 2 nausea/vomiting. The median patient age was 62 years old (range 36 -86 years) and the median follow-up was 14 months (range 2 -18 months). Five patients under went surgery after SBRT. The median overall survival was 14.5 months (range 2.4 -18.2 months), with 65.3% survival at one year. Median survival time is 15 month (range 12 -17 months). Median time to local progression has not been reached.
Conclusion:
In our experience, gating SBRT for pancreatic tumor is a well-tolerated feasible treatment. Most patients are free from local progression, but overall survival remains poor. Prospective studies are needed to define the role of SBRT for pancreatic tumors. Purpose or Objective: Stereotactic body radiotherapy (SBRT) in pancreatic cancer can be limited by its proximity to critical organs at risk (OAR) of the upper abdomen. In this study we evaluate the toxicity and efficacy of two different treatment approaches.
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Material and Methods:
Patients with recurrent or oligometastatic pancreas cancer were treated with SBRT. The planning target volume (PTV) was created through a 4 mm expansion of the internal target volume (ITV) based on a four dimensional CT (4D-CT). All patients were treated with intensity modulated radiation therapy (IMRT). In some cases we created a sub-volume, in order to reduce the risk of toxicity in critical adjacent OARs without compensating the whole PTV. This sub-volume was defined as a simultaneous integrated protection (SIP) PTV. The SIP consisted of the interface of the PTV with the planning risk volume (PRV) of a specific vulnerable structure at which we prescribed a predefined reduced dose.
Results: Between 2009 and 2014, 18 patients with 23 lesions were treated in our institution. Seven patients were treated for a local recurrence, nine were treated for oligometastases (liver, lymph nodes) and two patients were treated for both. Of these lesions 11 were treated with SIP and 12 were treated without SIP. The median follow up was 10.8 months (range 1.2-40.3 months). The freedom from local progression (FFLP) at 6 and 12 months was 90% and 84% respectively. The overall survival (OS) rates at 6 months and 12 months after SBRT were 77% and 54%, respectively. Two patients (11%) experienced grade >3 acute toxicity (mechanical ileus, gastrointestinal bleeding) and 2 patients (11%) experienced a grade > 3 late toxicity (cholangitis, bleeding).
Conclusion:
Local control and overall survival after SBRT in this high risk group of patients with pancreatic cancer were excellent despite of dose sacrifice in half of the patients when OARs were close to the PTV, with overall favourable toxicity. 
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Material and Methods:
We retrospectively analyzed patients with 1-2 secondary liver lesions treated with SABR. The total dose prescriptions were 30 Gy, 37.5 Gy and 45 Gy on three consecutive days in 42.8%, 22.8% and 34.4% of patients respectively. The dose was prescribed to the 80% isodose line covering the PTV. The primary endpoints were in field local control and toxicity; the secondary endpoint was survival rates.
Results: Between March 2007 and May 2015, 30 patients (17 males, 13 females) with 36 liver metastases were treated. The mean age was 66 years (range, 40-90 years). Twenty-five patients (83.3%) had a single hepatic lesion and the remaining 5 patients (16.7%) two hepatic lesions. Twenty patients (64.5%) had extrahepatic stable disease. The most frequent sites of primary tumor were colorectal (58%) and breast (20%). The majority of the lesions treated (75.6%) had a diameter of less than 3 cm. With a median follow-up of 21 months (range 2.3-69.8 months) for all patients, "in field" local response rate was 90%. No patient developed a toxicity greater than grade 2 according to CTC scale v4.02 and no radio-induced liver disease (RILD) was recorded. One-year LC and two-year LC were 62% and 39% respectively. One-year and two-year PFS were 46% and 25% (median, 11 months). One-year, two-year and three-year OS were 89%, 69 and 42% respectively, with a median survival time, calculated from the date of metastasis and last follow-up or death, of 29.8 months.
Conclusion:
These data suggest that stereotactic ablative radiotherapy (SABR) is a safe, non-invasive and effective option in the treatment of liver metastases. Predominant histological subtype was diffuse (43.4%) and poorly differentiated (grade 3, 50%). Complete resection (R0) was achieved 84.91%, whereas microscopic residual disease (R1) was found in 13.21%. Survival was calculated by KaplanMeier and method and differences were assessed by the Logrank test. Multivariate analysis was used Cox proportional hazards regression model.
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Results:
A total of 50 (47.16 %) patients relapsed; 16 (15.09%) locoregional, 13 (12.26%) peritoneal, 18 (16.98%) distant metastases and 3 (2.83%) unknown. The overall survival (OS), disease-free survival ( DFS), locoregional failure-free survival (LFS) rates to three years were 48.75%, 46.27% and 76.72% and to five years were 32.11%, 38.78%, 69.67% respectively. In univariate analysis, T stage (T1-T2), N negative stage and R0 resection were associated with better survival (p<0.05) for OS and only N negative stage for DFS and LFS. In the multivariate analysis indentified only R0 resection as an independent predictor of better survival (p<0.05) for OS and DFS.
Conclusion:
In this study, the prognostic factors associated with better survival in patients with LAGC treated with adyuvant radiochemotherapy were: T stage (T1-T2), N negative stage and R0 resection ( p< 0.05). Complete R0 resection also can be considered as independent prognostic factor of better survival (p<0.05)
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